DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationMRCS

Abdominal examination and stigmata of liver disease

Essential points for quick revision.

Synopsis

Perform a respectful, reproducible abdominal examination; recognise peritonism, decompensated liver disease, portal hypertension and an abdominal mass; and describe physical signs as probability-changing evidence rather than diagnoses.

  • Introduce yourself, confirm identity, explain the examination, obtain consent, offer a chaperone where appropriate, preserve dignity and ask about pain before positioning or exposure.
  • Start at the end of the bed: distress, colour, body habitus, muscle wasting, mobility, drains, stomas, oxygen and mental state may be more important than a single abdominal sign.
  • Examine hands, pulse, face, mouth, chest, abdomen, legs and cognition because chronic liver disease and systemic abdominal illness are not confined to the abdomen.

Key red flags

Peritonism and shock

Involuntary guarding, rigidity, percussion tenderness, absent movement with breathing, tachycardia, hypotension, cool peripheries or altered mental state suggests perforation, ischaemia, bleeding or severe inflammation.

Investigation priorities

01
Focused observations and bedside glucoseFirst step

Record NEWS2 elements, perfusion, urine output and glucose when acute abdominal or hepatic illness is possible.

Management branches

SequenceComplete abdominal examination

A stable patient consents to a clinically indicated abdominal assessment.

  1. Introduce, identify, explain, consent and position; ask about pain, expose appropriately and preserve dignity with a chaperone where indicated.
  2. Assess from the end of the bed, hands, pulse, face, mouth and chest, then inspect the abdomen before gentle and deep palpation.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom